Mark Wigglesworth

Mark Wigglesworth now leads AstraZeneca’s Global High Throughput Screening Centre and is an active member of the European Laboratory Research and Innovation Group (ELRIG) including co-director responsibility for their Research and Innovation conference for the last 3 years. Mark has contributed to numerous publications in the field of GPCR pharmacology, hit identification and Compound Management including editing a book describing the Management of Biological and Chemical Samples for Screening Applications. In his current role he leads a team of more than 20 scientists dedicated to identifying novel chemical starting points for drug discovery programmes and maintains a collaborative interest in Synthetic Biology